Literature DB >> 33482246

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.

E Baudin1, M Caplin2, R Garcia-Carbonero3, N Fazio4, P Ferolla5, P L Filosso6, A Frilling7, W W de Herder8, D Hörsch9, U Knigge10, C M Korse11, E Lim12, C Lombard-Bohas13, M Pavel14, J Y Scoazec15, A Sundin16, A Berruti17.   

Abstract

Keywords:  characterisation; diagnosis; lung carcinoids; prognosis; therapy; thymic carcinoids

Mesh：

Year:  2021        PMID： 33482246     DOI： 10.1016/j.annonc.2021.01.003

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  29 in total

1.  The role of quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis.

Authors:  Luohai Chen; Nuerailaguli Jumai; Qiao He; Man Liu; Yuan Lin; Yanji Luo; Yu Wang; Min-Hu Chen; Zhirong Zeng; Xiangsong Zhang; Ning Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10-01       Impact factor: 10.057

2.  Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors.

Authors:  Ahmet Bilgehan Sahin; Huseyin Melek; Birol Ocak; Sibel Oyucu Orhan; Buket Erkan; Burcu Caner; Adem Deligonul; Erdem Cubukcu; Ahmet Sami Bayram; Elif Ulker Akyildiz; Turkkan Evrensel
Journal:  Mol Clin Oncol       Date:  2022-08-09

3.  Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Authors:  Birgitta Hiddinga; Karen Zwaenepoel; Annelies Janssens; Jan Van Meerbeeck; Patrick Pauwels
Journal:  Oncotarget       Date:  2022-06-01

4.  Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise.

Authors:  Mirco Bartolomei; Alfredo Berruti; Massimo Falconi; Nicola Fazio; Diego Ferone; Secondo Lastoria; Giovanni Pappagallo; Ettore Seregni; Annibale Versari
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

5.  A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms.

Authors:  Esben Andreas Carlsen; Kristian Lindholm; Andreas Kjaer; Flemming Littrup Andersen; Amalie Hindsholm; Mathias Gæde; Claes Nøhr Ladefoged; Mathias Loft; Camilla Bardram Johnbeck; Seppo Wang Langer; Peter Oturai; Ulrich Knigge
Journal:  EJNMMI Res       Date:  2022-05-28       Impact factor: 3.434

6.  Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study.

Authors:  Hao Yang; Xinqi Xiao; Tonghua Mei; Ping Zhou
Journal:  Aging Clin Exp Res       Date:  2022-03-28       Impact factor: 4.481

7.  Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.

Authors:  Elisa Lenotti; Andrea Alberti; Francesca Spada; Vito Amoroso; Patrick Maisonneuve; Salvatore Grisanti; Alice Baggi; Susanna Bianchi; Nicola Fazio; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

Review 8.  Chemotherapy in NEN: still has a role?

Authors:  Paula Espinosa-Olarte; Anna La Salvia; Maria C Riesco-Martinez; Beatriz Anton-Pascual; Rocio Garcia-Carbonero
Journal:  Rev Endocr Metab Disord       Date:  2021-04-11       Impact factor: 9.306

9.  Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.

Authors:  B Kiesewetter; P Mazal; E Kretschmer-Chott; M E Mayerhoefer; M Raderer
Journal:  ESMO Open       Date:  2022-05-04

10.  Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.

Authors:  Anne-Leen Deleu; Annouschka Laenen; Herbert Decaluwé; Birgit Weynand; Christophe Dooms; Walter De Wever; Sander Jentjens; Karolien Goffin; Johan Vansteenkiste; Koen Van Laere; Paul De Leyn; Kristiaan Nackaerts; Christophe M Deroose
Journal:  EJNMMI Res       Date:  2022-05-07       Impact factor: 3.434
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.